Ibuproxam

Identification

Generic Name
Ibuproxam
DrugBank Accession Number
DB08955
Background

Ibuproxam is a non steroidal anti-inflammatory drug (NSAID).

Type
Small Molecule
Groups
Withdrawn
Structure
Weight
Average: 221.2955
Monoisotopic: 221.141578857
Chemical Formula
C13H19NO2
Synonyms
  • Ibuproxam
  • Ibuproxamum
  • p-Isobutylhydratropohydroxamic acid
External IDs
  • G 277
  • G-277

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirIbuproxam may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Abciximab.
AcebutololIbuproxam may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibuproxam.
AcemetacinThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Deflogon / Ibudros (Lucchini Laboratoire)

Categories

ATC Codes
M01AE13 — Ibuproxam
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Aromatic monoterpenoids
Alternative Parents
Monocyclic monoterpenoids / Phenylpropanes / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Aromatic homomonocyclic compound / Aromatic monoterpenoid / Benzenoid / Hydrocarbon derivative / Monocyclic benzene moiety / Monocyclic monoterpenoid / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
hydroxamic acid (CHEBI:76160)
Affected organisms
Not Available

Chemical Identifiers

UNII
O3LD16O96Z
CAS number
53648-05-8
InChI Key
BYPIURIATSUHDW-UHFFFAOYSA-N
InChI
InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)
IUPAC Name
N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide
SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO

References

Synthesis Reference

U.S. Patent 4,082,707.

General References
  1. Orzalesi G, Mari F, Bertol E, Selleri R, Pisaturo G: Anti-inflammatory agents: determination of ibuproxam and its metabolite humans. Correlation between bioavailability, tolerance and chemico-physical characteristics. Arzneimittelforschung. 1980;30(9):1607-9. [Article]
KEGG Drug
D07268
PubChem Compound
68704
PubChem Substance
310264920
ChemSpider
61955
BindingDB
50012894
ChEBI
76160
ChEMBL
CHEMBL292707
Wikipedia
Ibuproxam

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Suppository
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)119-121U.S. Patent 4,082,707.
Predicted Properties
PropertyValueSource
Water Solubility0.073 mg/mLALOGPS
logP2.77ALOGPS
logP3.03Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.83Chemaxon
pKa (Strongest Basic)-5.5Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area49.33 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity64.32 m3·mol-1Chemaxon
Polarizability25.08 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-07vi-3900000000-1f77a4c97febd785dc71
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fr-1960000000-ca7832f2055bb8341606
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fk9-0290000000-87c21e811b2abcd83cf8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01bc-2910000000-f10003d96f7d03307bd8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01qc-2900000000-49ffaed9464fde0689d7
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-3900000000-fc06edd923ddabf45570
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014l-6910000000-8486772c0b794f36e70a
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-152.0183
predicted
DeepCCS 1.0 (2019)
[M+H]+154.3763
predicted
DeepCCS 1.0 (2019)
[M+Na]+161.0135
predicted
DeepCCS 1.0 (2019)

Drug created at May 28, 2014 19:10 / Updated at June 12, 2020 16:52